Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.53 | 14.99 | 17.61 | 21.23 | 45.18 | 2.73 | 10.83 | 3.96 | 6.45 | 3.11 |
Net Debt/EBITDA |
1.12 | 2.58 | 2.82 | 4.01 | 6.66 | 2.72 | 0.74 | 0.92 | 0.97 | 0.40 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.86 | 0.82 | 0.70 | 0.77 | 0.80 | 0.52 | 0.53 | 0.39 | 0.62 | 0.84 |
Capex/Depreciation |
(1.44) | (1.12) | (0.61) | (3.37) | (0.39) | (0.19) | (0.14) | (2.51) | 0.00 | (0.03) |
| (62.74%) | (31.39%) | (28.80%) | (21.10%) | (25.11%) | (114.42%) | (182.33%) | (342.46%) | (213.05%) | (186.26%) | |
| (56.06%) | (29.54%) | (27.39%) | (20.36%) | (22.39%) | (77.90%) | (131.55%) | (230.17%) | (173.71%) | (122.62%) | |
ROIC |
0.00% | (6,100.04%) | (801.74%) | (248.52%) | (777.78%) | 0.00% | (2,321.12%) | 0.00% | 0.00% | (35,321.81%) |
Return on Tangible Assets |
(93.06%) | (36.70%) | (34.60%) | (23.94%) | (14.92%) | (82.34%) | (132.30%) | (263.38%) | (159.94%) | (281.51%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.15 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(3.46) | (2.51) | (2.49) | (2.46) | (2.11) | (15.35) | (16.12) | (32.72) | (101.45) | (328.28) |
Cash per Share |
4.81 | 8.48 | 10.53 | 13.14 | 17.50 | 52.58 | 22.39 | 37.83 | 111.88 | 187.99 |
Shareholders Equity per Share |
4.57 | 8.52 | 10.82 | 13.97 | 17.71 | 36.02 | 23.22 | 31.75 | 106.75 | 188.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.57 | 8.52 | 10.82 | 13.97 | 17.71 | 36.02 | 23.22 | 31.75 | 106.75 | 188.85 |
Free Cash Flow |
(29.78) | (21.05) | (20.95) | (20.79) | (16.48) | (11.58) | (9.14) | (9.07) | (6.59) | (5.38) |
Working Capital |
37.36 | 69.49 | 86.98 | 112.63 | 138.11 | 27.10 | 13.00 | 8.63 | 6.67 | 2.21 |
Capital Expenditures |
(0.02) | (0.02) | (0.01) | (0.03) | (0.01) | (0.01) | (0.01) | (0.11) | — | (0.01) |
Net Current Asset Value |
37.36 | 69.49 | 86.98 | 112.63 | 138.11 | 27.10 | 12.99 | 8.63 | 6.67 | 2.21 |
| Other line items | ||||||||||
Quick Ratio |
5.02 | 14.33 | 16.92 | 20.07 | 44.00 | 2.57 | 10.15 | 3.78 | 6.23 | 2.94 |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.24 | 1.53 | 0.81 | 11.22 | 5.51 |
Cash ROIC |
(36.88%) | (14.75%) | (11.67%) | (9.08%) | (6.00%) | (17.33%) | (35.35%) | (47.02%) | (46.40%) | (87.12%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(3.46) | (2.51) | (2.49) | (2.46) | (2.11) | (15.34) | (16.11) | (32.32) | (101.45) | (327.72) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.40) | 0.00 | (0.56) |
Average Receivables |
— | — | — | 0.91 | 0.85 | 0.69 | 0.63 | 0.44 | 0.25 | — |
Average Payables |
2.49 | 0.74 | 1.89 | 2.34 | 1.65 | 0.94 | 0.32 | 0.34 | 0.29 | 0.53 |
Average Assets |
62.03 | 86.35 | 109.89 | 132.40 | 92.05 | 28.66 | 13.11 | 9.94 | 6.15 | 5.19 |
Average Common Equity |
55.42 | 81.25 | 104.49 | 127.76 | 82.05 | 19.52 | 9.46 | 6.68 | 5.02 | 3.42 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026